Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide

Au, 2001, Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features, Hum. Pathol., 32, 126, 10.1053/hupa.2001.21128 Avvisati, 1996, AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study, Blood, 88, 1390, 10.1182/blood.V88.4.1390.bloodjournal8841390 Bashey, 1992, Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): implications for the role of N-ras mutation in AML pathogenesis, Blood, 79, 981, 10.1182/blood.V79.4.981.bloodjournal794981 Beitinjaneh, 2010, Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review, Leuk. Res., 34, 831, 10.1016/j.leukres.2010.01.001 Bowen, 2005, RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60years, Blood, 106, 2113, 10.1182/blood-2005-03-0867 Cancer Genome Atlas Research N, 2013, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N. Engl. J. Med., 368, 2059, 10.1056/NEJMoa1301689 Chan, 2006, Oncogenic K-ras cooperates with PML–RAR alpha to induce an acute promyelocytic leukemia-like disease, Blood, 108, 1708, 10.1182/blood-2006-04-015040 Chen, 1994, Retinoic acid and acute promyelocytic leukemia: a model of targetting treatment for human cancer, C. R. Acad. Sci. III, 317, 1135 Chen, 1996, In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML–RAR alpha/PML proteins, Blood, 88, 1052, 10.1182/blood.V88.3.1052.1052 Chen, 2009, Epigenetic alterations in a murine model for chronic lymphocytic leukemia, Cell Cycle, 8, 3663, 10.4161/cc.8.22.9957 Chen, 2013, Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition, Genes Dev., 27, 1974, 10.1101/gad.226613.113 Cheson, 2003, Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 21, 4642, 10.1200/JCO.2003.04.036 Creutzig, 2004, Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 22, 3432, 10.1200/JCO.2004.99.116 Damm, 2011, Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups, Leukemia, 25, 1704, 10.1038/leu.2011.142 De Botton, 1998, Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group, Blood, 92, 2712, 10.1182/blood.V92.8.2712 de la Serna, 2008, Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin, Blood, 111, 3395, 10.1182/blood-2007-07-100669 Degos, 1995, All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia, Blood, 85, 2643, 10.1182/blood.V85.10.2643.bloodjournal85102643 Dicker, 2011, Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML, Leukemia, 24, 1528, 10.1038/leu.2010.124 Estey, 1999, Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia, Blood, 94, 2230, 10.1182/blood.V94.7.2230.419k05_2230_2235 Estey, 2005, Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid, Blood, 105, 1366, 10.1182/blood-2004-09-3437 Fenaux, 1994, Treatment of newly diagnosed acute promyelocytic leukemia (APL) by a combination of all-trans retinoic acid (ATRA) and chemotherapy. French APL Group, Leukemia, 8, S42 Gill, 1992, Multistate life-tables and regression models, Math. Popul. Stud., 3, 259, 10.1080/08898489209525345 Goto, 2011, Missense mutations in PML–RARA are critical for the lack of responsiveness to arsenic trioxide treatment, Blood, 118, 1600, 10.1182/blood-2011-01-329433 Hu, 2009, Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia, Proc. Natl. Acad. Sci. U. S. A., 106, 3342, 10.1073/pnas.0813280106 Huang, 1988, Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia, Blood, 72, 567, 10.1182/blood.V72.2.567.567 Ito, 2008, PML targeting eradicates quiescent leukaemia-initiating cells, Nature, 453, 1072, 10.1038/nature07016 Jasielec, 2014, The mechanistic role of DNA methylation in myeloid leukemogenesis, Leukemia, 28, 1765, 10.1038/leu.2014.163 Jeanne, 2010, PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3, Cancer Cell, 18, 88, 10.1016/j.ccr.2010.06.003 Jeong, 2014, Large conserved domains of low DNA methylation maintained by Dnmt3a, Nat. Genet., 46, 17, 10.1038/ng.2836 Lallemand-Breitenbach, 1999, Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia, J. Exp. Med., 189, 1043, 10.1084/jem.189.7.1043 Lo-Coco, 2013, Retinoic acid and arsenic trioxide for acute promyelocytic leukemia, N. Engl. J. Med., 369, 111, 10.1056/NEJMoa1300874 Lou, 2013, High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia, Leuk. Res., 37, 37, 10.1016/j.leukres.2012.09.004 Muindi, 1992, Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia, Blood, 79, 299, 10.1182/blood.V79.2.299.299 Nasr, 2010, Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting, Int. J. Hematol., 91, 742, 10.1007/s12185-010-0582-0 Nasr, 2008, Eradication of acute promyelocytic leukemia-initiating cells through PML–RARA degradation, Nat. Med., 14, 1333, 10.1038/nm.1891 Niu, 1999, Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients, Blood, 94, 3315, 10.1182/blood.V94.10.3315.422k16_3315_3324 Raffoux, 2003, Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 21, 2326, 10.1200/JCO.2003.01.149 Rajendra, 2012, Management of acute promyelocytic leukemia: implications for treatment of other cancers, Oncology (Williston Park), 26, 641 Rampal, 2011, Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models, J. Clin. Invest., 121, 1255, 10.1172/JCI57200 Sanz, 2011, Modern approaches to treating acute promyelocytic leukemia, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 29, 495, 10.1200/JCO.2010.32.1067 Sanz, 2000, Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups, Blood, 96, 1247 Schar, 2011, DNA repair and the control of DNA methylation, Prog. Drug Res., 67, 51 Shen, 2001, Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage, Leukemia, 15, 735, 10.1038/sj.leu.2402106 Shen, 2004, All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia, Proc. Natl. Acad. Sci. U. S. A., 101, 5328, 10.1073/pnas.0400053101 Shen, 2011, Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia, Blood, 118, 5593, 10.1182/blood-2011-03-343988 Tallman, 2009, How I treat acute promyelocytic leukemia, Blood, 114, 5126, 10.1182/blood-2009-07-216457 Villa, 2007, Role of the polycomb repressive complex 2 in acute promyelocytic leukemia, Cancer Cell, 11, 513, 10.1016/j.ccr.2007.04.009 Wang, 2013, Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China, Proc. Natl. Acad. Sci. U. S. A., 110, 17017, 10.1073/pnas.1315558110 Wang, 2010, PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia, Cancer Cell, 17, 186, 10.1016/j.ccr.2009.12.045 Yan, 2011, Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia, Nat. Genet., 43, 309, 10.1038/ng.788 Zhang, 2010, Arsenic trioxide controls the fate of the PML-–RARalpha oncoprotein by directly binding PML, Science, 328, 240, 10.1126/science.1183424 Zheng, 2005, Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia, Proc. Natl. Acad. Sci. U. S. A., 102, 7653, 10.1073/pnas.0502825102 Zhou, 2010, Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia, Blood, 115, 1697, 10.1182/blood-2009-07-230805 Zhu, 1997, Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia, Proc. Natl. Acad. Sci. U. S. A., 94, 3978, 10.1073/pnas.94.8.3978 Zhu, 1999, Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents, Leukemia, 13, 1062, 10.1038/sj.leu.2401448 Zhu, 2007, RXR is an essential component of the oncogenic PML/RARA complex in vivo, Cancer Cell, 12, 23, 10.1016/j.ccr.2007.06.004 Zhu, 2013, Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 31, 4215, 10.1200/JCO.2013.48.8312